These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17208672)

  • 1. Evaluation of the Xal-Ease latanoprost delivery system.
    Semes L; Shaikh AS
    Optometry; 2007 Jan; 78(1):30-3. PubMed ID: 17208672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation in Number of Doses, Bottle Volume, and Calculated Yearly Cost of Generic and Branded Latanoprost for Glaucoma.
    Queen JH; Feldman RM; Lee DA
    Am J Ophthalmol; 2016 Mar; 163():70-74.e1. PubMed ID: 26596398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xal-Ease: impact of an ocular hypotensive delivery device on ease of eyedrop administration, patient compliance, and satisfaction.
    Nordmann JP; Baudouin C; Bron A; Denis P; Rouland JF; Sellem E; Renard JP
    Eur J Ophthalmol; 2009; 19(6):949-56. PubMed ID: 19882583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The physical properties of generic latanoprost ophthalmic solutions are not identical.
    Kolko M; Koch Jensen P
    Acta Ophthalmol; 2017 Jun; 95(4):370-373. PubMed ID: 28229536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.
    Wang RF; Gagliuso DJ; Mittag TW; Podos SM
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4143-7. PubMed ID: 17724199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of latanoprost when stored at room temperature.
    Mochizuki H; Itakura H; Takamatsu M; Kiuchi Y
    Hiroshima J Med Sci; 2008 Jun; 57(2):69-72. PubMed ID: 18717189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost analysis of the prostaglandin analogs.
    Mick AB; Gonzalez S; Dunbar MT; McSoley JJ
    Optometry; 2002 Oct; 73(10):614-9. PubMed ID: 12408547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of eyedrop instillation technique with and without a delivery device in inexperienced patients.
    Gomes BF; Lordello M; Celli LF; Santhiago MR; Moraes HV
    Eur J Ophthalmol; 2016 Nov; 26(6):594-597. PubMed ID: 27135092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma.
    Yildirim N; Sahin A; Gultekin S
    J Glaucoma; 2008; 17(1):36-9. PubMed ID: 18303382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations.
    Angmo D; Wadhwani M; Velpandian T; Kotnal A; Sihota R; Dada T
    Int Ophthalmol; 2017 Apr; 37(2):423-428. PubMed ID: 27334605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma.
    Quaranta L; Pizzolante T; Riva I; Haidich AB; Konstas AG; Stewart WC
    Br J Ophthalmol; 2008 Sep; 92(9):1227-31. PubMed ID: 18586898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily cost of glaucoma medications in China.
    Gao Y; Wu L; Li A
    J Glaucoma; 2007; 16(7):594-7. PubMed ID: 18091176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops.
    Kahook MY; Noecker R
    Adv Ther; 2008 Aug; 25(8):743-51. PubMed ID: 18670744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An objective assessment of the variability in number of drops per bottle of glaucoma medication.
    Moore DB; Beck J; Kryscio RJ
    BMC Ophthalmol; 2017 May; 17(1):78. PubMed ID: 28532424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials.
    Varma R; Hwang LJ; Grunden JW; Bean GW
    Am J Ophthalmol; 2008 Feb; 145(2):336-42. PubMed ID: 18222194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy and performance of a commercially available Dosing Aid.
    Cronin TH; Kahook MY; Lathrop KL; Noecker RJ
    Br J Ophthalmol; 2007 Apr; 91(4):497-9. PubMed ID: 16916873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma.
    Nakamoto K; Yasuda N
    J Glaucoma; 2007; 16(4):352-7. PubMed ID: 17570997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation between office intraocular pressure and 24-hour intraocular pressure in patients with primary open-angle glaucoma treated with a combination of topical antiglaucoma eye drops.
    Nakakura S; Nomura Y; Ataka S; Shiraki K
    J Glaucoma; 2007 Mar; 16(2):201-4. PubMed ID: 17473730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.